Relative Bioavailability of 100 mg Nintedanib (Ofev) Given as Four Capsules of 25 mg Compared to One Capsule of 100 mg Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
Latest Information Update: 19 Jul 2023
Price :
$35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Bladder cancer; Breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Idiopathic pulmonary fibrosis; Inflammatory breast cancer; Interstitial lung diseases; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Pulmonary fibrosis; Renal cell carcinoma; Salivary gland cancer; Soft tissue sarcoma; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Sep 2021 Status changed from active, no longer recruiting to completed.
- 23 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2021 Status changed from not yet recruiting to recruiting.